Meihao Medical (301363.SZ): The US government's related tariff policies have not had a negative impact on the company's business.

Gelonghui Finance · Jul 16 03:18

Mei Hao Medical (301363.SZ) stated on the investor interaction platform on July 16th that, up to now, the US government’s relevant policy of imposing additional tariffs has not had a negative impact on the company's business. Firstly, the company's main customers are located in places such as Singapore and Australia, and the end products are exported from Singapore and Australia to the United States and other places for sales. Secondly, since establishing its first overseas production base in Malaysia in 2014, the company has been orderly expanding production based on customer demand. The first and second phase plants are already in normal production and the company continues to enhance the full-chain delivery capability of its overseas production base. Currently, it is accelerating the expansion of the third phase production base in Malaysia, which is expected to be delivered and put into use two years later. Finally, the company's supply chain strategy is a dual-cycle of domestic and international circulation. For customers' end markets overseas, the company directly provides customers with tailored production capacity and services to resolve policy and geopolitical risks including, but not limited to, tariffs.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

美好医疗(301363.SZ)：美国政府相关加征关税政策未对公司的业务产生负面影响

Meihao Medical (301363.SZ): The US government's related tariff policies have not had a negative impact on the company's business.

Risk Disclaimer

Statement